Pharmafile Logo
Pharmafocus logo
Advanced Search

Ocrevus

Showing 13 posts of 13 posts found.

needle-1291170_960_720

Genentech shares results from phase 3 trial for MS treatment

July 13, 2023
Research and Development Genentech, MS, Neurology, Ocrevus, clinical trial

Genentech has announced positive results from its phase 3 OCARINA II trial which assessed Ocrevus (ocrelizumab) as a twice-a-year, ten-minute …

News

Multi-study data confirms Ocrevus’ long-term efficacy in reducing disability progression in multiple sclerosis

September 13, 2019
Medical Communications, Research and Development ECTRIMS, Ocrevus, Roche, multiple sclerosis, pharma

Roche has taken the opportunity at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in Stockholm …

News
genentech_web

Ocrevus becomes first NICE-approved therapy on the NHS for primary progressive multiple sclerosis

May 9, 2019
Sales and Marketing Genentech, NHS, NICE, Ocrevus, UK

NICE has announced its final appraisal decision on Genentech’s Ocrevus (ocrelizumab), choosing to recommend the drug for use on the …

News
roche__tree

Roche’s Ocrevus shows earlier, better outcomes in primary progressive and relapsing MS

October 11, 2018
Research and Development Ocrevus, Roche, multiple sclerosis, pharma

Roche has unveiled new five-year data from three Phase 3 open-label extension studies investigating the efficacy of Ocrevus (ocrelizumab) in …

News

NICE rejects Roche’s Ocrevus in primary progressive multiple sclerosis

September 10, 2018
Sales and Marketing NICE, Ocrevus, Roche, UK, multiple sclerosis, pharma

Of the 100,000 MS patients in England, around one in eight have the primary progressive form (PPMS), which brings debilitating …

News

NICE turns down Roche’s Ocrevus in early primary progressive multiple sclerosis

June 29, 2018
Medical Communications, Sales and Marketing NICE, Ocrevus, Roche, pharma

Roche’s sometimes strained relationship with NICE continues as the health watchdog for England and Wales chose to reject the former’s …

News
roche

Roche’s Ocrevus extends time-to-wheelchair by 7 years in progressive MS patients

June 14, 2018
Research and Development Ocrevus, Roche, multiple sclerosis, pharma

Roche has lifted the curtain on more promising data at Phase 3 for its humanised anti-CD20 monoclonal antibody Ocrevus (ocrelizumab), …

News
roche_close

Roche suffers Ocrevus knockback by NICE

April 6, 2018
Medical Communications, Sales and Marketing Ocrevus, Roche, biotech, drugs, multiple sclerosis, pharma, pharmaceutical

Roche’s multiple sclerosis drug, Ocrevus (ocrelizumab), has been a big new growth driver for the company, especially in the US, …

News
roche_close

Roche’s Ocrevus gets the go ahead in Europe for two forms of MS

January 12, 2018
Medical Communications, Sales and Marketing Europe, European Commission, Ocrevus, Roche, multiple sclerosis, pharma

Roche has revealed that its multiple sclerosis (MS) drug Ocrevus (ocrelizumab) has been awarded marketing approval in Europe by the …

News
roche_dark_0

EMA recommends approval of Roche’s Ocrevus in relapsing forms of multiple sclerosis

November 13, 2017
Sales and Marketing MS, Ocrevus, Roche, multiple sclerosis, pharma

Roche has revealed that its humanised monoclonal antibody Ocrevus (ocrelizumab) received a positive recommendation from the Committee for Medical Products …

News
roche

Roche chalks up Swiss approval for multiple sclerosis drug Ocrevus

September 28, 2017
Sales and Marketing Ocrevus, Roche, multiple sclerosis, pharma, pharmaceutical

Roche has announced that its drug Ocrevus (ocrelizumab) has received marketing approval in Switzerland for the treatment of active relapsing …

News
images

Roche’s Ocrevus more effective than Merck’s Rebif, company claims

September 14, 2016
Research and Development Merck, Ocrevus, Rebif, Roche, multiple sclerosis

Roche has announced new results from the Phase III studies of investigational medicine Ocrevus (ocrelizumab) studying relapsing multiple sclerosis (RMS) …

News

Roche says EMA accepts its marketing applications for Ocrevus to treat multiple sclerosis

June 28, 2016
Manufacturing and Production, Research and Development, Sales and Marketing EMA, Ocrevus, Roche, US FDA, drug development, drug trial, multiple sclerosis, priority review, regulation

Cancer drugmaker Roche (SIX: ROG) said the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for its …

News

Latest content

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023

NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment

September 27, 2023

Alfasigma to acquire Intercept Pharmaceuticals for $19 per share

September 27, 2023

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023